Krystal Biotech Stock: VYJUVEK’s Success Is Becoming Its Growth Problem (Downgrade)
· seekingalpha.com
Krystal Biotech is downgraded from Buy to Hold as U.S. VYJUVEK sales plateau and growth shifts ex-U.S. Read more on KRYS stock here.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...